Most read guides

GLP-1 costs: what can change month to month

A practical guide to comparing GLP-1 pricing, including medication cost, memberships, shipping, insurance assumptions, and why “starting at” rarely tells the whole story.

GLP-1 eligibility: who may qualify and what clinicians review

What telehealth programs usually screen for before starting GLP-1 treatment, including BMI context, health history, and why intake forms do not replace clinician judgment.

How to evaluate a GLP-1 telehealth program: a due diligence guide

Not all GLP-1 telehealth programs are equal. A practical framework for evaluating clinical oversight, medication sourcing, cost transparency, support quality, and red flags before you subscribe.

Getting started with a GLP-1 program: a step-by-step checklist

A practical checklist covering everything from choosing a provider to your first injection, including what to prepare, what to expect during intake, and how to set up for long-term success.

GLP-1 for type 2 diabetes vs weight management: key differences

The same molecules are approved for both conditions but at different doses, under different brand names, with different insurance coverage rules. Here is what patients and providers need to separate.

Weight loss plateaus on GLP-1: what the data shows and what to do

Clinical trial data shows that GLP-1 weight loss follows a predictable curve that flattens into a plateau. Here is what the STEP and SURMOUNT trials reveal about the timeline, the biology behind plateaus, and evidence-based strategies for continued progress.

What is GLP‑1? Basics and safety

A plain-English overview of GLP‑1 programs and how they work.

GLP-1 insurance and Medicare coverage in 2026

How commercial insurance, Medicare Part D, and the new Medicare GLP-1 Bridge program handle coverage for weight-management medications like Wegovy and Zepbound in 2026.

GLP-1 peptide classes explained: single, dual, and triple agonists

Understanding the difference between pure GLP-1 agonists, dual GIP/GLP-1 agonists, glucagon combinations, and amylin hybrids helps you make sense of the rapidly expanding weight-loss drug landscape.

Oral GLP-1 pills: Wegovy pill and Foundayo explained

The first oral GLP-1 medications for weight management are now available. How Wegovy pill and Foundayo compare on efficacy, convenience, pricing, and what to expect from oral dosing.

Semaglutide vs tirzepatide: comparing the two leading GLP-1 medications

A head-to-head comparison of semaglutide (Wegovy) and tirzepatide (Zepbound) covering mechanism, efficacy data, side effect profiles, dosing, pricing, and which drug fits which patient profile.

GLP-1 peptide classes explained: single, dual, and triple agonists

Understanding the difference between pure GLP-1 agonists, dual GIP/GLP-1 agonists, glucagon combinations, and amylin hybrids helps you make sense of the rapidly expanding weight-loss drug landscape.

The GLP-1 pipeline: every weight-loss peptide in development (2026)

A complete guide to the next generation of weight-loss peptides beyond Wegovy and Zepbound — including retatrutide, CagriSema, amycretin, survodutide, VK2735, and what happened to Pfizer’s danuglipron.

Retatrutide: the triple-agonist GLP-1 that hit 28.7% weight loss

Eli Lilly's retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 TRIUMPH-4 showed 28.7% weight loss at 68 weeks — the highest ever recorded in an obesity trial. Here is what we know about the mechanism, trial data, side effects, and timeline.

Research peptides for weight loss: why "for research only" is not a loophole

The FDA, state regulators, and clinical evidence are clear: research-grade peptides sold online are not safe substitutes for FDA-approved GLP-1 medications. Here is what the regulations say, what the risks are, and what has gone wrong.

GLP-1 and pregnancy: what patients need to know

Why GLP-1 medications are contraindicated in pregnancy, how long to wait before conceiving, and what the prescribing information says about fertility, breastfeeding, and male partners.

Compounded GLP-1 medications: risks, regulations, and what to ask

Compounded semaglutide and tirzepatide are not FDA-approved. Here is what compounding actually means, the regulatory timeline that changed the market, safety data from FDA adverse event reports, and the questions to ask before using a compounded product.

GLP-1 drug interactions: what your prescriber should check

GLP-1 medications delay gastric emptying, which can change how your body absorbs other drugs. Here is what the clinical data shows for oral contraceptives, levothyroxine, warfarin, insulin, and other commonly co-prescribed medications.

GLP-1 side effects and safety basics

The common side effects readers hear about most, which serious warnings still matter, and why compounded GLP-1 products need a separate safety conversation.